微信公众号
证券之星APP
| 报告期 | 净资产收益率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 4.32% | -14.46% | 58.82% | 68/160 | 4.14% | 百利天恒 | 186.1% | 行业排名> |
| 2024-06-30 | 2.72% | -10.82% | 104.51% | 67/160 | 2.6% | 百利天恒 | 186.89% | 行业排名> |
| 2024-03-31 | 1.33% | -38.71% | -70.11% | 81/160 | 2.3% | 百利天恒 | 188.56% | 行业排名> |
| 2023-12-31 | 4.45% | -52.61% | -11.88% | 67/160 | -0.96% | 小方制药 | 41.8% | 行业排名> |
| 2023-09-30 | 5.05% | -17.08% | 65.57% | 70/160 | 2.37% | 拓新药业 | 20.51% | 行业排名> |
| 2023-06-30 | 3.05% | -37.11% | 40.55% | 68/160 | 1.51% | 拓新药业 | 19.87% | 行业排名> |
| 2023-03-31 | 2.17% | 83.9% | -76.89% | 58/160 | 1.38% | 拓新药业 | 19.91% | 行业排名> |
| 2022-12-31 | 9.39% | 9.44% | 54.19% | 48/160 | 0.8% | 小方制药 | 55.57% | 行业排名> |
| 2022-09-30 | 6.09% | -35.21% | 25.57% | 57/160 | 2.89% | 福元医药 | 25.41% | 行业排名> |
| 2022-06-30 | 4.85% | 15.48% | 311.02% | 49/160 | 2.24% | 小方制药 | 34.81% | 行业排名> |
| 2022-03-31 | 1.18% | -48.02% | -86.25% | 86/160 | 1.61% | 退市金泰 | 10.74% | 行业排名> |
| 2021-12-31 | 8.58% | 6.72% | -8.72% | 52/160 | 0.94% | 人福医药 | 6.82% | 行业排名> |
| 2021-09-30 | 9.4% | 25% | 123.81% | 37/160 | 4.53% | 小方制药 | 71.99% | 行业排名> |
| 2021-06-30 | 4.2% | 4.48% | 85.02% | 68/160 | 2.99% | 汇宇制药 | 39.25% | 行业排名> |
| 2021-03-31 | 2.27% | 25.41% | -71.77% | 63/160 | 2.52% | 汇宇制药 | 28.14% | 行业排名> |
| 2020-12-31 | 8.04% | 3.47% | 6.91% | 69/160 | 3.74% | 哈三联 | 27.17% | 行业排名> |
| 2020-09-30 | 7.52% | 4.3% | 87.06% | 53/160 | 3.22% | 汇宇制药 | 55.94% | 行业排名> |
| 2020-06-30 | 4.02% | -2.43% | 122.1% | 66/160 | 4.24% | 河化股份 | 45.32% | 行业排名> |
| 2020-03-31 | 1.81% | -27.89% | -76.71% | 53/160 | 2.24% | 汇宇制药 | 31.9% | 行业排名> |
| 2019-12-31 | 7.77% | -1.89% | 7.77% | 73/160 | 2.78% | 誉衡药业 | 35.56% | 行业排名> |
| 2019-09-30 | 7.21% | -9.88% | 75% | 50/160 | 7.61% | 奥赛康 | 35% | 行业排名> |
| 2019-06-30 | 4.12% | -12.53% | 64.14% | 62/160 | 5.05% | 奥赛康 | 28.15% | 行业排名> |
| 2019-03-31 | 2.51% | -13.45% | -68.31% | 44/160 | 2.46% | 宏源药业 | 21.91% | 行业排名> |
| 2018-12-31 | 7.92% | -18.94% | -1% | 68/160 | 7.09% | 奥赛康 | 9.7% | 行业排名> |
| 2018-09-30 | 8% | -21.95% | 69.85% | 40/160 | 7.26% | 奥赛康 | 40.69% | 行业排名> |
| 2018-06-30 | 4.71% | -15.89% | 62.41% | 46/160 | 4.65% | 信立泰 | 25.93% | 行业排名> |
| 2018-03-31 | 2.9% | -12.12% | -70.32% | 33/160 | 2.55% | 昂利康 | 15.91% | 行业排名> |
| 2017-12-31 | 9.77% | -8.09% | -4.68% | 51/160 | 9.66% | 奥赛康 | 12.08% | 行业排名> |
| 2017-09-30 | 10.25% | -10.64% | 83.04% | 27/160 | 8.31% | 一品红 | 31.62% | 行业排名> |
| 2017-06-30 | 5.6% | -7.28% | 69.7% | 37/160 | 5.59% | 丽珠集团 | 49.43% | 行业排名> |
| 2017-03-31 | 3.3% | -3.51% | -68.96% | 22/160 | 2.1% | 河化股份 | 54.24% | 行业排名> |
| 2016-12-31 | 10.63% | 11.08% | -7.32% | 52/160 | 6.33% | 华东医药 | 7.2% | 行业排名> |
| 2016-09-30 | 11.47% | 3.71% | 89.9% | 20/160 | 5.61% | 南新制药 | 81.7% | 行业排名> |
| 2016-06-30 | 6.04% | 19.13% | 76.61% | 34/160 | 3.53% | 德展健康 | 29.5% | 行业排名> |
| 2016-03-31 | 3.42% | 9.27% | -64.26% | 21/160 | 2.65% | 贝达药业 | 16.78% | 行业排名> |
| 2015-12-31 | 9.57% | 13.52% | -13.47% | 52/160 | 11.35% | 河化股份 | 19.29% | 行业排名> |
| 2015-09-30 | 11.06% | 17.29% | 118.15% | 20/160 | 7.22% | 一品红 | 58.17% | 行业排名> |
| 2015-06-30 | 5.07% | 16.02% | 61.98% | 36/160 | 4.9% | 华东医药 | 36.97% | 行业排名> |
| 2015-03-31 | 3.13% | 17.23% | -62.87% | 27/160 | 2.41% | 华东医药 | 26.63% | 行业排名> |